论文部分内容阅读
目的观察重组人促红细胞生成素联合铁剂治疗早产儿贫血的疗效。方法 80例早产儿随机分为对照组和观察组,各40例。对照组给予常规治疗,观察组在对照组基础上给予重组人促红细胞生成素联合铁剂治疗,比较两组治疗后疗效。结果治疗后第2、4周各检测时间点观察组血红蛋白(Hb)、血细胞压积(Hct)及网织红细胞计数(Ret)改善水平均优于对照组,差异均有统计学意义(P<0.05);在胎龄满40周时观察组患儿新生儿神经行为测定(NBNA)评分高于对照组,差异有统计学意义(P<0.05)。结论重组人促红细胞生成素联合铁剂可有效治疗早产儿贫血,减少输血次数,且用药安全,值得临床推广。
Objective To observe the effect of recombinant human erythropoietin combined with iron on the treatment of anemia in premature infants. Methods 80 cases of premature children were randomly divided into control group and observation group, 40 cases each. The control group was given routine treatment. The observation group was given recombinant human erythropoietin combined with iron on the basis of the control group. The curative effect was compared between the two groups. Results The improvement of hemoglobin (Hb), hematocrit (Hct) and reticulocyte count (Ret) in observation group at 2, 4 weeks after treatment were all better than those in control group (P < 0.05). Neonatal neurobehavioral assessment (NBNA) score in observation group was higher than that in control group at 40 weeks of gestational age, the difference was statistically significant (P <0.05). Conclusion Recombinant human erythropoietin combined with iron can effectively treat anemia in premature infants, reduce the number of transfusions and safe use of drugs, which is worthy of clinical promotion.